14-day Premium Trial Subscription Sign Up For FreeGet Free

Stock Market Week 20 - The Game Is On! Click to watch.

Clovis Oncology Stock Forecast

NASDAQ:CLVS BUY SELL

$0.83 (6.10%)

Volume: 4.573M

Closed: May 16, 2022

Hollow Logo Score: -4.635

Clovis Oncology Stock Forecast

BUY SELL NASDAQ:CLVS
$0.83 (6.10%)

Volume: 4.573M

Closed: May 16, 2022

Score Hollow Logo -4.635

Clovis Oncology Stock Forecast NASDAQ:CLVS

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-06 - HC Wainwright & Co. - Downgrades Buy Neutral
2022-05-05 381.93% HC Wainwright & Co. $5.00 $4.00 Maintains Buy
2021-09-21 984.34% HC Wainwright & Co. $10.00 $9.00 Maintains Buy
2021-08-05 1104.82% HC Wainwright & Co. $12.00 $10.00 Maintains Buy
2021-05-05 1345.78% HC Wainwright & Co. $13.00 $12.00 Maintains Buy
2020-11-06 1707.23% HC Wainwright & Co. $23.00 $15.00 Maintains Buy
2020-11-06 261.45% SVB Leerink $4.00 $3.00 Maintains Underperform
2020-05-22 3393.98% HC Wainwright & Co. $33.00 $29.00 Reiterates Buy
2020-05-20 381.93% SVB Leerink $5.00 $4.00 Maintains Underperform
2020-05-18 3875.9% HC Wainwright & Co. $29.00 $33.00 Maintains Buy
2020-05-06 3393.98% HC Wainwright & Co. $27.00 $29.00 Reiterates Buy
2020-04-27 502.41% SVB Leerink $5.00 Downgrades Market Perform Underperform
2020-04-09 622.89% B of A Securities $6.00 Downgrades Neutral Underperform
2020-01-23 1104.82% B of A Securities $7.00 $10.00 Maintains Neutral
2019-11-19 863.86% Evercore ISI Group $8.00 Downgrades Outperform In-Line
2019-10-08 261.45% Goldman Sachs $13.00 $3.00 Maintains Sell
2019-09-24 - SVB Leerink - Downgrades Outperform Market Perform
2019-08-13 743.37% B of A Securities $13.00 $7.00 Downgrades Buy Neutral
2019-08-02 - Guggenheim - Downgrades Buy Neutral
2019-05-29 1707.23% Goldman Sachs $17.00 $15.00 Downgrades Neutral Sell

CLVS Stock Trend

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.74 is broken, it will firstly indicate a stronger fall rate.

Given the current short-term trend, the stock is expected to fall -5.53% during the next 3 months and, with a 90% probability hold a price between $0.70 and $2.72 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-05-18 $0.74 $1.81 $2.88
2022-05-19 $0.73 $1.81 $2.88
2022-05-20 $0.73 $1.80 $2.87
2022-05-23 $0.73 $1.80 $2.87
2022-05-24 $0.73 $1.80 $2.87
2022-05-25 $0.72 $1.79 $2.86
2022-05-26 $0.72 $1.79 $2.86
2022-05-27 $0.72 $1.79 $2.86
2022-05-31 $0.71 $1.79 $2.86
2022-06-01 $0.71 $1.78 $2.85
2022-06-02 $0.71 $1.78 $2.85
2022-06-03 $0.71 $1.78 $2.85
2022-06-06 $0.70 $1.77 $2.84
2022-06-07 $0.70 $1.77 $2.84
2022-06-08 $0.70 $1.77 $2.84
2022-06-09 $0.70 $1.77 $2.84
2022-06-10 $0.69 $1.76 $2.83
2022-06-13 $0.69 $1.76 $2.83
2022-06-14 $0.69 $1.76 $2.83
2022-06-15 $0.68 $1.75 $2.83
2022-06-16 $0.68 $1.75 $2.82
2022-06-17 $0.68 $1.75 $2.82
2022-06-21 $0.68 $1.75 $2.82
2022-06-22 $0.67 $1.74 $2.81
2022-06-23 $0.67 $1.74 $2.81
2022-06-24 $0.67 $1.74 $2.81
2022-06-27 $0.66 $1.73 $2.81
2022-06-28 $0.66 $1.73 $2.80
2022-06-29 $0.66 $1.73 $2.80
2022-06-30 $0.66 $1.73 $2.80

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucapar... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT